REG - Silence Therapeutics - Additional Listing and Total Voting Rights

Silence TherapeuticsAnnouncement

12/02/2021 12:15

RNS Number : 9785O
  
Silence Therapeutics PLC
  
12 February 2021
  
 

 
Additional Listing and Total Voting Rights
February 12, 2021
 
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that further to the Company's press release on 5 February 2021 of a private placement of 2,022,218 of the Company's American Depositary Shares ("ADSs"), each representing three ordinary shares of 5 pence each in the capital of the Company (the "Private Placement"), it has issued 6,066,654 new ordinary shares of 5p each (the "New Ordinary Shares").  The Private Placement closed on 9 February 2021 and the New Ordinary Shares were admitted to trading on AIM on 10 February 2021.  
 
The total number of ordinary shares in issue as at 12 February 2021 is 89,398,841. The Company holds no shares in Treasury.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. 
 
 
Enquiries:
 



Silence Therapeutics plc
Gem Hopkins, Head of IR & Corporate Communications
ir@silence-therapeutics.com
 
 


Tel:   +1 (646) 637-3208




  Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


  Tel:  +44 (0) 20 7597 5970




 


 



 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ALSDKBBKBBKDCBD